Neoadjuvant Pembrolizumab Trial Shows High pCR Rate and No Relapses at 3 Years in High-Risk dMMR/MSI-High Colorectal Cancer

Neoadjuvant Pembrolizumab Trial Shows High pCR Rate and No Relapses at 3 Years in High-Risk dMMR/MSI-High Colorectal Cancer

April 24, 2026

When the OncLive headline broke on April 24, 2026, announcing that neoadjuvant pembrolizumab produced a high pathological complete response rate with zero relapses at three years in high-risk dMMR/MSI-high colorectal cancer, it wasn’t just another oncology update scrolling through feeds—it landed with particular resonance in communities like Austin, Texas, where colorectal cancer rates among adults under 50 have risen sharply over the past decade, prompting local health systems to reevaluate screening protocols and treatment accessibility. This isn’t abstract science; it’s a potential shift in how we approach one of the most feared diagnoses, especially for younger patients facing aggressive disease.

The NEOPRISM-CRC trial, referenced across multiple sources including the ASCO presentation and subsequent coverage, provides the concrete foundation for this optimism. Researchers enrolled 32 patients with operable high-risk stage II or III dMMR/MSI-high colorectal cancer, stratifying them by tumor mutation burden (TMB). Those with high or medium TMB received three cycles of pembrolizumab before surgery, while those with low TMB received one cycle. The intent-to-treat population showed a 53% pathological complete response rate, climbing to 58% in the evaluable tumor group. Critically, for the high/medium TMB subgroup—the focus of the three-year follow-up—the pCR rate was 55% in intent-to-treat and 59% in evaluable analyses. Perhaps most striking, the updated data revealed zero relapses among responders at the three-year mark, a durability signal that transforms pembrolizumab from a preoperative tool into a potential curative paradigm for this molecularly defined subset.

This precision approach builds on earlier signals from metastatic settings like KEYNOTE-177, where pembrolizumab outperformed chemotherapy in dMMR/MSI-high colorectal cancer, but NEOPRISM-CRC redirects that power earlier in the disease course. By administering immunotherapy before surgery, the trial aims not just to shrink tumors but to eradicate microscopic disease, potentially reducing the demand for aggressive postoperative chemotherapy and its long-term toxicities. The translational endpoints—analyzing blood, tissue, and microbiome for predictive biomarkers—suggest future refinements could further personalize who benefits most, sparing low-TMB patients unnecessary exposure while intensifying strategies for others.

For Austin residents, this data intersects with local realities in meaningful ways. The city’s demographic profile—young, diverse, and rapidly growing—means colorectal cancer is increasingly diagnosed in working-age adults navigating careers, families, and the unique stresses of life in a booming tech hub. Institutions like the Livestrong Cancer Institutes at the Dell Medical School, UT Health Austin’s gastrointestinal oncology team, and the cancer prevention initiatives at MD Anderson’s Austin campus are already grappling with rising early-onset cases. NEOPRISM-CRC’s findings could influence how these entities structure neoadjuvant therapy pathways, particularly for patients with Lynch syndrome or other hereditary risks prevalent in Central Texas populations.

the trial’s emphasis on TMB stratification introduces a layer of complexity that demands robust local infrastructure. Accurate TMB assessment requires sophisticated genomic sequencing and bioinformatics support—resources available at major academic centers but potentially uneven across community hospitals. In Austin, this highlights the ongoing need for investment in molecular pathology labs at facilities like Seton Medical Center, and St. David’s South Austin Medical Center, ensuring that biomarker-driven decisions aren’t limited to those who can travel to specialty centers. The ripple effects extend to insurance navigation, genetic counseling access, and survivorship programs tailored to younger patients facing unique concerns about fertility, career continuity, and long-term monitoring.

Given my background in translating complex medical advances into actionable community insights, if this trend impacts you or someone you know in the Austin area, here are three types of local professionals you’ll wish to engage:

  • Genomic Oncology Specialists: Glance for physicians or molecular pathologists with explicit expertise in colorectal cancer biomarkers, particularly dMMR/MSI-H and TMB testing. They should be affiliated with institutions participating in NCI-designated cancer center networks or have demonstrable experience interpreting genomic reports to guide immunotherapy sequencing—ask about their involvement in trials or institutional protocols for neoadjuvant PD-1 inhibition.
  • Gastrointestinal Surgical Oncologists: Seek surgeons who routinely manage locally advanced rectal and colon cancer and have published or presented on neoadjuvant therapy pathways. Key criteria include volume (high numbers of complex cancer surgeries annually), multidisciplinary tumor board participation, and experience coordinating timing between immunotherapy cycles and surgical intervention to maximize pathologic response without compromising operability.
  • Oncology-Focused Genetic Counselors: Prioritize counselors with specific training in hereditary gastrointestinal syndromes like Lynch syndrome, who can assess family history, facilitate germline testing, and interpret results in the context of immunotherapy eligibility. They should operate closely with oncology teams to ensure genetic findings inform not just risk assessment but also treatment selection and family communication strategies.

Ready to find trusted professionals? Browse our complete directory of top-rated experts in the Austin area today.